OUTLINE: This is a phase I, dose-escalation study of cabozantinib followed by a phase II, dose-expansion study.
Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients also undergo standard of care radiation therapy for 5-6 weeks.
After completion of study treatment, patients are followed up at 30 days, every 12 weeks for up to 1 year, then every 6 months for up to 3 years.
How understandable was the trial content above?
Hard to understand
Easy to understand
